Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
about
Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor ActivityRegulating the Regulators: Recent Revelations in the Control of E3 Ubiquitin LigasesBuilding and remodelling Cullin-RING E3 ubiquitin ligasesStructure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomideDifferentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogsImmunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.New agents for the treatment of lymphoid leukemia and lymphoma: focus on recent FDA approvals.The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myelomaThe combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.Effect of thalidomide on the proliferation of hepatoma cells assessed by osteopontin levels in nude mice.Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat.In silico analysis of enantioselective binding of immunomodulatory imide drugs to cereblon.Differential effects of lenalidomide during plasma cell differentiationCombination immune therapies to enhance anti-tumor responses by NK cells.Pomalidomide: a review of its use in patients with recurrent multiple myeloma.Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.Pericytes as targets in hereditary hemorrhagic telangiectasia.Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin LymphomaEvaluation of US 2016/0115161 A1: isoindoline compounds and methods of their use.Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity.Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.Electronic circular dichroism behavior of chiral Phthiobuzone.Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance.Innovations in treatment and response evaluation in multiple myeloma.LNO3 AND L3 Are Associated With Antiproliferative And Pro-Apoptotic Action In Hepatoma Cells.Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery.Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.CUL5 is required for thalidomide-dependent inhibition of cellular proliferation.Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents.
P2860
Q26773135-FF5C0BB3-B61A-486C-AAF9-AE6E20FA18B6Q26799441-7BFE9293-8243-4290-9474-04B735DC66DBQ27027816-8985E429-C8D4-41F7-AFBF-5B13963891D4Q27684738-82C9C1A3-51DE-4A0C-ACEC-62723C09AFD5Q34661167-ED8D2F0E-D75A-4084-B6E1-266A10B24DAEQ35801267-B688E65F-3BA1-48E0-8242-B0562653BA55Q35951381-599CC3ED-8317-4517-BBAA-A45EA98FF24FQ36414249-2450D504-BE78-430C-B92E-FA2D765BD701Q36833480-82884840-59C3-4CAF-9CCE-D65F5BBAFE49Q36900631-C5924E85-6BE7-4D6E-A9CF-1C633ADAD40BQ37045248-ED16A3C2-A021-4F9E-91AB-399C3F9C9F1FQ37104408-F9B8EEB5-426B-4D42-9AC5-A9297083DC11Q37317494-74D5BC22-0D6B-4799-ADEE-2682BA38F05BQ37408550-6374CDEF-FEA0-4E38-8921-D6C9D5D37789Q38192969-8AF7C1C1-46FB-4BA0-852F-B603BE3FD2BEQ38231991-C001469F-0475-445F-B888-CB3E4CDD9D8EQ38374758-6201A723-FB24-44FE-9B0B-DB8EF4C9477AQ38551337-4EB322B5-A155-4FA1-82B3-BC5BB933E0C7Q38689884-00DEDCFC-DD13-42F5-8FA3-38FE8779EF07Q38724074-8FCF43C3-1C1A-44C3-9CAC-B6E9B36DF357Q38758162-920BF5FF-08ED-4D48-83EB-0267CEF8EF31Q39007207-25DAE99D-274A-451D-A8A8-8624D620B159Q41518616-D1CB6EC6-2FB4-4326-9A7D-81CB45C58635Q42042886-B49A37F1-DBAE-4209-BF95-7AD8FF84DA11Q42399891-EC428FF9-18AB-42CB-BF7B-F1D8388F1800Q42577709-15A24216-D9BA-4F46-821C-C5F1BF33B6B3Q42696060-C1C9097F-C264-4FBE-937B-54E3816A0CF2Q47128290-6AD29D1A-2CD0-486A-8173-C1410D29F6EDQ53158997-3F8B5010-D0CB-4450-B0BE-F09749A6C3D7Q54215914-DC2D407C-BCA2-423E-BA74-469F2BA88617Q55007606-3535E22E-3311-43A7-BD93-5DD50036DE75
P2860
Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Thalidomide-analogue biology: ...... tic targets in cancer therapy.
@en
type
label
Thalidomide-analogue biology: ...... tic targets in cancer therapy.
@en
prefLabel
Thalidomide-analogue biology: ...... tic targets in cancer therapy.
@en
P2860
P356
P1433
P1476
Thalidomide-analogue biology: ...... etic targets in cancer therapy
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2012.599
P407
P577
2013-01-14T00:00:00Z
P5875
P6179
1034046475